- Home
- QCRH vs VRDN Comparison
QCRH vs VRDN Comparison
Compare QCRH & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- VRDN
- Stock Information
- Founded
- QCRH 1993
- VRDN 2006
- Country
- QCRH United States
- VRDN United States
- Employees
- QCRH N/A
- VRDN N/A
- Industry
- QCRH Major Banks
- VRDN Medical Specialities
- Sector
- QCRH Finance
- VRDN Health Care
- Exchange
- QCRH Nasdaq
- VRDN Nasdaq
- Market Cap
- QCRH 1.3B
- VRDN 1.5B
- IPO Year
- QCRH 1993
- VRDN N/A
- Fundamental
- Price
- QCRH $77.47
- VRDN $19.37
- Analyst Decision
- QCRH Buy
- VRDN Strong Buy
- Analyst Count
- QCRH 3
- VRDN 11
- Target Price
- QCRH $88.83
- VRDN $38.80
- AVG Volume (30 Days)
- QCRH 82.5K
- VRDN 863.3K
- Earning Date
- QCRH 10-22-2025
- VRDN 11-11-2025
- Dividend Yield
- QCRH 0.31%
- VRDN N/A
- EPS Growth
- QCRH N/A
- VRDN N/A
- EPS
- QCRH 6.63
- VRDN N/A
- Revenue
- QCRH $322,873,000.00
- VRDN $305,000.00
- Revenue This Year
- QCRH N/A
- VRDN N/A
- Revenue Next Year
- QCRH $7.11
- VRDN $35,092.81
- P/E Ratio
- QCRH $11.76
- VRDN N/A
- Revenue Growth
- QCRH N/A
- VRDN 5.90
- 52 Week Low
- QCRH $60.83
- VRDN $9.90
- 52 Week High
- QCRH $96.08
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- QCRH 53.86
- VRDN 56.96
- Support Level
- QCRH $75.96
- VRDN $18.12
- Resistance Level
- QCRH $78.50
- VRDN $20.51
- Average True Range (ATR)
- QCRH 1.66
- VRDN 0.90
- MACD
- QCRH -0.30
- VRDN 0.02
- Stochastic Oscillator
- QCRH 28.60
- VRDN 54.58
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).